Opposing interests make it hard to define what elements are essential for a competitive marketplace.
As a recent report from Amgen made clear, biosimilars are gaining ground in the biologics marketplace, but across drug categories the pace of this advance is highly uneven.
Which of these is most characteristic of a healthy biologics marketplace?
Check out the results from our last poll:
Click to enlarge